What is the recommended dosing regimen for acyclovir in an adult, including oral and intravenous routes and adjustments for renal impairment?

Acyclovir Dosing in Adults

For adults with normal renal function, oral acyclovir is dosed at 200 mg five times daily or 400 mg every 12 hours for herpes simplex prophylaxis, while intravenous acyclovir is dosed at 5-10 mg/kg every 8 hours for severe infections like herpes simplex encephalitis, with mandatory dose adjustments based on creatinine clearance in renal impairment. 1, 2, 3

Oral Dosing Regimens

Herpes Simplex Prophylaxis

• Standard dose: 200 mg three times daily OR 400 mg every 12 hours 1
• Alternative: 200 mg every 12 hours for patients with creatinine clearance <10 mL/min 1

Herpes Zoster Treatment

• Standard dose: 800 mg five times daily 2
• Treatment should be initiated within 72 hours of rash onset for optimal efficacy 4

Genital Herpes

• First episode: 200 mg orally 5 times daily for 7-10 days 5
• Recurrent episodes: 200 mg 5 times daily, 400 mg 3 times daily, or 800 mg twice daily for 5 days 5
• Suppressive therapy: 400 mg twice daily (can reduce to 200 mg 3-5 times daily as alternative) 5

Intravenous Dosing Regimens

Herpes Simplex Encephalitis

• Standard dose: 10 mg/kg IV every 8 hours for 14-21 days 6, 3
• Higher dose consideration: 20 mg/kg IV every 8 hours for 21 days has shown improved outcomes in neonates and may be considered in severe cases 6
• Infuse over 1 hour to minimize nephrotoxicity risk 3

Severe Herpes Infections

• Immunocompromised patients: 5-10 mg/kg IV every 8 hours for 5-7 days 5
• Disseminated disease: 5-10 mg/kg IV every 8 hours until clinical resolution 5

VZV Encephalitis

• Standard dose: 10 mg/kg IV three times daily 4
• Alternative: 15 mg/kg IV three times daily if renal function is normal (requires frequent monitoring) 4

Renal Dose Adjustments

Critical caveat: Acyclovir is primarily renally eliminated (62-91% unchanged), making dose adjustment essential in renal impairment to prevent neurotoxicity and nephrotoxicity 3.

Oral Acyclovir Adjustments

• CrCl <10 mL/min: 200 mg every 12 hours 1
• Hemodialysis: 200 mg every 12 hours; administer first daily dose after dialysis 1

Intravenous Acyclovir Adjustments (for standard 5 mg/kg dose)

The FDA label provides specific guidance 3:

• CrCl >50 mL/min: No adjustment needed (standard every 8 hours)
• CrCl 25-50 mL/min: Standard dose every 12 hours
• CrCl 10-25 mL/min: Standard dose every 24 hours
• CrCl 0-10 mL/min: 50% of standard dose every 24 hours
• Hemodialysis: 2.5 mg/kg after each dialysis session 7

For higher doses (10 mg/kg for encephalitis), proportional adjustments apply with the same interval modifications 8.

Special Populations

Obese Patients

Use adjusted body weight (AdjBW) or ideal body weight (IBW) rather than total body weight to calculate IV acyclovir doses 9. Total body weight dosing increases AKI risk significantly (17.3% vs 7% with IBW) without clear therapeutic benefit 9. The adjusted odds ratio for AKI with IBW dosing is 0.27 compared to total body weight 9.

Elderly Patients

Dose reduction is necessary due to age-related decline in renal function 3. Calculate creatinine clearance (not just serum creatinine) and adjust accordingly, as elderly patients achieve higher plasma concentrations 3.

End-Stage Renal Disease

For dialysis-dependent patients 10, 11:

• Loading dose: 400 mg
• Maintenance: 200 mg twice daily
• Post-dialysis supplementation: 400 mg after each dialysis session
• Standard 800 mg doses cause neurotoxicity in this population 10, 11

Critical Safety Considerations

Nephrotoxicity Prevention

• Maintain adequate hydration before and during therapy 12, 2
• Avoid rapid IV bolus; infuse over at least 1 hour 12, 3
• Monitor renal function: baseline, then every 2-3 times weekly during induction, every 1-2 weeks during maintenance 12
• AKI occurs in 13-38% of patients, with higher rates in those with pre-existing renal impairment or diabetes 13

Neurotoxicity Recognition

Presents as confusion, hallucinations, agitation, tremors, or seizures 10, 11, 14. Risk factors include:

• Renal impairment (most important)
• Elderly age
• High doses without renal adjustment
• Concurrent nephrotoxic drugs

Management: Hemodialysis removes 51-61.5% of acyclovir and provides both diagnostic confirmation and therapeutic intervention 10, 7.

Drug Interactions

Probenecid increases acyclovir half-life and AUC by reducing renal clearance 3. Avoid concurrent nephrotoxic agents (aminoglycosides, NSAIDs, contrast) 12.

Monitoring Parameters

• Baseline: Serum creatinine, BUN, electrolytes
• During therapy:
  • Renal function every 2-3 days initially, then weekly
  • Neurological status daily
  • Hydration status
• For encephalitis: Consider repeat CSF PCR at end of therapy; positive result warrants continued treatment 6

The half-life increases from 2.5 hours with normal renal function to 19.5 hours in anuric patients, emphasizing the critical importance of dose adjustment 3.